metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
ovarian cancer (OC) ovarian cancer (OC)
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
	AGO-OVAR 2.29/ENGOT-ov34, 2024 Int J Gynecol Cancer 2020 Dec;30(12):1997-2001. NCT03353831	RCT	ovarian cancer (OC)	atezolizumab	Soc	recurrent ovarian, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after completing platinum-based chemotherapy or 3rd relapse	285 / 289	NA	inconclusive	inconclusive 17 % decrease in deaths (OS) (PE) inconclusive 13 % decrease in progression or deaths (PFS) (PE)
metastatic/advanced OC (mOC) - 1st line (L1) metastatic/advanced OC (mOC) - 1st line (L1)
versus bevacizumab plus carboplatin and paclitaxel
	atezolizumab plus bevacizumab plus carboplatin plus paclitaxel
	AGO-OVAR 2.29/ENGOT-ov34, 2024 Int J Gynecol Cancer 2020 Dec;30(12):1997-2001. NCT03353831	RCT	ovarian cancer (OC)	atezolizumab	Soc	recurrent ovarian, fallopian tube, or primary peritoneal cancer with 1st or 2nd relapse within 6 months after completing platinum-based chemotherapy or 3rd relapse	285 / 289	NA	inconclusive	inconclusive 17 % decrease in deaths (OS) (PE) inconclusive 13 % decrease in progression or deaths (PFS) (PE)
mOC - L1 - all population metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - all population
versus placebo plus SoC
	atezolizumab plus SoC
	IMagyn-050 (all population), 2021 Int J Gynecol Cancer 2019 Jan 10;ijgc-2018-000071. J Clin Oncol 2021 Apr 23;JCO2100306. NCT03038100	RCT	mOC - L1 - all population	atezolizumab plus paclitaxel carboplatin and bevacizumalb	placeb plus paclitaxel carboplatin and bevacizumalb	patients with stage III or stage IV epithelial ovarian, fallopian tube, or primaryperitoneal cancer with either macroscopic residual disease or who will undergo neoadjuvant chemotherapy followed by interval surgery	651 / 650	low	inconclusive	inconclusive 4 % decrease in deaths (OS) (PE) inconclusive 8 % decrease in progression or deaths (PFS) (PE)
mOC - L1 - PDL1 positive metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - PDL1 positive
versus placebo plus SoC
	atezolizumab plus SoC
	IMagyn-050 (PDL1 >1%), 2021 Int J Gynecol Cancer 2019 Jan 10;ijgc-2018-000071. J Clin Oncol 2021 Apr 23;JCO2100306. NCT03038100	RCT	mOC - L1 - PDL1 positive	atezolizumab plus paclitaxel carboplatin and bevacizumalb	placeb plus paclitaxel carboplatin and bevacizumalb	patients with stage III or stage IV epithelial ovarian, fallopian tube, or primaryperitoneal cancer with either macroscopic residual disease or who will undergo neoadjuvant therapy followed by interval surgery, PDL1 positive population	391 / 393	low	suggested	inconclusive 2 % decrease in deaths (OS) (PE) suggested 20 % decrease in progression or deaths (PFS) (PE)
metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)
versus pegylated liposomal doxorubicin
	avelumab alone
	JAVELIN ovarian 200 (A vs doxorubicin), 2021 Future Oncol 2018 Sep;14(21):2103-2113. Lancet Oncol 2021 Jun 15;S1470-2045(21)00216-3. NCT02580058	RCT	metastatic/advanced OC (mOC) - 2nd line (L2)	avelumab	Pegylated liposomal doxorubicin	Patients with platinum-resistant/refractory epithelial ovarian, fallopian tube, or peritoneal cancer, unselected for PD-L1 expression (ovarian cancer) a maximum of three previous lines for platinum-sensitive disease (most recent line containing platinum) with no previous systemic therapy for platinum-resistant disease	188 / 190	some concern	inconclusive	inconclusive 14 % increase in deaths (OS) (PE) statistically significant 68 % increase in progression or deaths (PFS) (PE)
	avelumab plus pegylated liposomal doxorubicin
	JAVELIN ovarian 200 (A/doxorubicin vs doxorubicin), 2021 Future Oncol 2018 Sep;14(21):2103-2113. Lancet Oncol 2021 Jun 15;S1470-2045(21)00216-3. NCT02580058	RCT	metastatic/advanced OC (mOC) - 2nd line (L2)	avelumab plus PLD	Pegylated liposomal doxorubicin	Patients with platinum-resistant/refractory epithelial ovarian, fallopian tube, or peritoneal cancer, unselected for PD-L1 expression (ovarian cancer) a maximum of three previous lines for platinum-sensitive disease (most recent line containing platinum) with no previous systemic therapy for platinum-resistant disease	188 / 190	some concern	inconclusive	inconclusive 11 % decrease in deaths (OS) (PE) inconclusive 22 % decrease in progression or deaths (PFS) (PE)
metastatic/advanced OC (mOC) - maintenance (M) metastatic/advanced OC (mOC) - maintenance (M)
versus rucaparib
	nivolumab based treatment
	ATHENA-COMBO (GOG-3020/ENGOT-ov45), 2021 Int J Gynecol Cancer 2021 Sep 30;ijgc-2021-002933. NCT03522246	RCT	metastatic/advanced OC (mOC) - maintenance (M)	combination of rucaparib (Rubraca®) andnivolumab as maintenance treatment	rucaparib alone	women with newly diagnosed ovarian cancer who responded to their first-line chemotherapy.	-/-	NA	no results	no results from press release May 31 2024 : The primary endpoint of investigator-assessed progression-free survival (PFS) comparing the combination of rucaparib and nivolumab with rucaparib monotherapy was not met in the intent-to-treat (ITT) population

ovarian cancer (OC) ovarian cancer (OC)

metastatic/advanced OC (mOC) - 1st line (L1) metastatic/advanced OC (mOC) - 1st line (L1)

mOC - L1 - all population metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - all population

mOC - L1 - PDL1 positive metastatic/advanced OC (mOC) - 1st line (L1) mOC - L1 - PDL1 positive

metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)

metastatic/advanced OC (mOC) - maintenance (M) metastatic/advanced OC (mOC) - maintenance (M)